Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

3 Jun 2019

Abstract excerpt

BET-bromodomain inhibition (BETi) has shown pre-clinical promise for MYC-amplified medulloblastoma. However, the mechanisms for its action, and ultimately for resistance, have not been fully defined. Here, using a combination of expression profiling, genome-scale CRISPR/Cas9-mediated loss of function and ORF/cDNA driven rescue screens, and cell-based models of spontaneous resistance, we identify bHLH/homeobox...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31160565
DOI: 10.1038/s41467-019-10307-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaPMID 31160565Read ↗

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionSemantic proximity Read ↗

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.Semantic proximity Read ↗

Targeting CBP/p300 Overcomes Acquired Vincristine Resistance in MedulloblastomaSemantic proximity Read ↗

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsSemantic proximity Read ↗

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genesSemantic proximity Read ↗

BET Bromodomain Inhibition of <i>MYC</i> -Amplified MedulloblastomaSemantic proximity Read ↗

Functional Genomic Screens Reveal RBBP4 as a Key Regulator of Cell Cycle Progression in TMZ-Resistant GlioblastomaSemantic proximity Read ↗

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitorsSemantic proximity Read ↗

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitorSemantic proximity Read ↗

R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.Semantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.